文献速递乳腺癌

DCE-MRI特征预测非肿块强化型乳腺癌新辅助化疗疗效

[Predictive value of dynamic contrast-enhanced magnetic resonance imaging features for the efficacy of neoadjuvant chemotherapy in breast cancer patients with non-mass enhancement].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

本研究回顾性纳入285例非肿块强化型乳腺癌患者,分析DCE-MRI特征对新辅助化疗后pCR的预测价值及与预后的关联。ADC预测pCR的AUC为0.813,Kep为0.756,最佳截断值分别为0.895×10-3 mm2/s和1.305 min-1。ADC<0.895×10-3 mm2/s和Kep>1.305 min-1是不利因素及DFS独立危险因素。

要点

  • ADC预测pCR的AUC为0.813,最佳截断值0.895×10-3 mm2/s。
  • Kep预测pCR的AUC为0.756,最佳截断值1.305 min-1。
  • ADC<0.895×10-3 mm2/s和Kep>1.305 min-1者DFS显著缩短。

核心结论

  • ADC和Kep是非肿块强化型乳腺癌患者新辅助化疗疗效和预后的潜在影像学标志物。

研究设计与样本

  • 回顾性纳入2021年1月至2023年12月中国医科大学附属盛京医院收治的非肿块强化型乳腺癌患者285例,均接受新辅助化疗。
  • 按新辅助化疗后是否达到pCR分为pCR组(n=132)和非pCR组(n=153)。
  • 随访截至2025年11月,中位随访时间41个月。

主要发现

  • ADC预测pCR的AUC为0.813(95% CI:0.765~0.860,P<0.001),Kep为0.756(95% CI:0.702~0.811,P<0.001)。
  • 淋巴结转移(OR=0.382)、三阴性乳腺癌(OR=0.396)、ADC<0.895×10-3 mm2/s(OR=0.189)、Kep>1.305 min-1(OR=0.281)是pCR的不利因素(均P<0.05)。
  • ADC<0.895×10-3 mm2/s和Kep>1.305 min-1是病情进展的独立危险因素,DFS显著缩短,HR分别为2.659和2.759(均P<0.001)。

关键数值与推荐

  • ADC最佳截断值为0.895×10-3 mm2/s,Kep最佳截断值为1.305 min-1。

临床怎么用

  • 可利用DCE-MRI的ADC和Kep参数辅助预测非肿块强化型乳腺癌新辅助化疗后pCR概率及DFS风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the potential predictive value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) features for the efficacy of neoadjuvant chemotherapy in breast cancer patients with non-mass enhancement on MRI, and to analyze their correlation with patient prognosis. Methods: A total of 285 breast cancer patients with non-mass enhancement on MRI admitted to Shengjing Hospital of China Medical University between January 2021 and December 2023 were retrospectively included. All patients underwent neoadjuvant chemotherapy, and were divided into a pathologic complete response (pCR) group (n=132) and a non-pCR group (n=153) based on whether they achieved pCR after neoadjuvant chemotherapy. Differences in DCE-MRI features and other clinicopathological characteristics between the two groups were analyzed. Receiver operating characteristic (ROC) curves were used to determine the optimal cutoff values for different DCE-MRI feature parameters. Multivariate logistic regression models were employed to analyze factors influencing pCR after neoadjuvant chemotherapy in breast cancer patients, and multivariate Cox regression models were used to analyze factors influencing disease-free survival (DFS). Followed-up continued until November 2025, with a median follow-up duration of 41 months. Results: The ROC curves showed that the areas under the curve for the apparent diffusion coefficient (ADC) and rate constant (Kep) in predicting pCR in breast cancer patients with non-mass enhancement on MRI after neoadjuvant chemotherapy were 0.813 (95% CI: 0.765-0.860, P<0.001) and 0.756 (95% CI: 0.702-0.811, P<0.001), respectively. The optimal cutoff values were 0.895×10-3 mm2/s and 1.305 min-1, respectively. Lymph node metastasis (OR=0.382), triple-negative breast cancer (OR=0.396), ADC<0.895×10-3 mm2/s (OR=0.189), and Kep>1.305 min-1 (OR=0.281) were identified as adverse factors for pCR in breast cancer patients with non-mass enhancement on MRI after neoadjuvant chemotherapy (all P<0.05). Multivariate Cox regression analysis revealed that an ADC<0.895×10-3 mm2/s and Kep>1.305 min-1 were independent risk factors for disease progression after neoadjuvant chemotherapy in breast cancer patients with non-mass enhancement. Patients with these DCE-MRI characteristics had significantly shorter disease-free survival (DFS), with hazard ratios (HRs) of 2.659 and 2.759, respectively (both P<0.001). Conclusion: ADC and Kep are potential biomarkers for the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer patients with non-mass enhancement. 目的: 分析乳腺动态增强磁共振(DCE-MRI)特征对非肿块强化型乳腺癌患者新辅助化疗疗效的潜在预测价值,并分析其与患者预后的关联。 方法: 回顾性收集2021年1月至2023年12月中国医科大学附属盛京医院收治的非肿块强化型乳腺癌患者285例。所有患者均接受了新辅助化疗,根据患者新辅助化疗后是否达到病理完全缓解(pCR),将患者分为pCR组(n=132)和非pCR组(n=153),分析两组患者DCE-MRI特征及其他临床病理特征的差异。使用受试者操作特征(ROC)曲线判断不同DCE-MRI特征参数的最佳截断值。通过多因素logistic回归模型分析乳腺癌患者新辅助化疗后pCR的影响因素,多因素Cox回归模型分析患者无病生存时间(DFS)的影响因素。随访截至2025年11月,中位随访时间41个月。 结果: ROC曲线显示,表观扩散系数和速率常数(Kep)预测非肿块强化型乳腺癌患者新辅助化疗后pCR的曲线下面积分别为0.813(95% CI:0.765~0.860,P<0.001)和0.756(95% CI:0.702~0.811,P<0.001),最佳截断值分别为0.895×10-3 mm2/s和1.305 min-1。淋巴结转移(OR=0.382)、三阴性乳腺癌(OR=0.396)、表观扩散系数<0.895×10-3 mm2/s(OR=0.189)、Kep>1.305 min-1(OR=0.281)是非肿块强化型乳腺癌患者新辅助化疗后pCR的不利因素(均P<0.05)。多因素Cox回归分析显示,表观扩散系数<0.895×10-3 mm2/s、Kep>1.305 min-1是非肿块强化型乳腺癌患者新辅助化疗后病情进展的独立危险因素,具有该类DCE-MRI特征的患者DFS显著缩短,HR分别为2.659和2.759(均P<0.001)。 结论: 表观扩散系数和Kep是非肿块强化型乳腺癌患者新辅助化疗疗效和预后的潜在影像学标志物。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu ZJ, Han Y, Yu H, et al. [Predictive value of dynamic contrast-enhanced magnetic resonance imaging features for the efficacy of neoadjuvant chemotherapy in breast cancer patients with non-mass enhancement]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42927952. doi:10.3760/cma.j.cn112152-20260104-00004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。